DE122005000033I2 - Kalzium-Receptor aktive Verbindungen - Google Patents
Kalzium-Receptor aktive VerbindungenInfo
- Publication number
- DE122005000033I2 DE122005000033I2 DE1995633948 DE69533948C DE122005000033I2 DE 122005000033 I2 DE122005000033 I2 DE 122005000033I2 DE 1995633948 DE1995633948 DE 1995633948 DE 69533948 C DE69533948 C DE 69533948C DE 122005000033 I2 DE122005000033 I2 DE 122005000033I2
- Authority
- DE
- Germany
- Prior art keywords
- phenyl
- substits
- substd
- opt
- naphthyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/28—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by unsaturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
- C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1994/012117 WO1995011221A1 (en) | 1991-08-23 | 1994-10-21 | Calcium receptor-active arylalkyl amines |
US08/353,784 US6011068A (en) | 1991-08-23 | 1994-12-08 | Calcium receptor-active molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
DE122005000033I2 true DE122005000033I2 (de) | 2006-11-23 |
Family
ID=23390556
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE1995633948 Active DE122005000033I2 (de) | 1994-10-21 | 1995-10-23 | Kalzium-Receptor aktive Verbindungen |
DE200512000033 Pending DE122005000033I1 (de) | 1994-10-21 | 1995-10-23 | Kalzium-Rezeptor aktive Verbindungen. |
DE69533948T Expired - Lifetime DE69533948T2 (de) | 1994-10-21 | 1995-10-23 | Kalzium-Rezeptor aktive Verbindungen |
DE69535461T Expired - Lifetime DE69535461T2 (de) | 1994-10-21 | 1995-10-23 | Kalzium-rezeptor aktive verbindungen |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE200512000033 Pending DE122005000033I1 (de) | 1994-10-21 | 1995-10-23 | Kalzium-Rezeptor aktive Verbindungen. |
DE69533948T Expired - Lifetime DE69533948T2 (de) | 1994-10-21 | 1995-10-23 | Kalzium-Rezeptor aktive Verbindungen |
DE69535461T Expired - Lifetime DE69535461T2 (de) | 1994-10-21 | 1995-10-23 | Kalzium-rezeptor aktive verbindungen |
Country Status (25)
Country | Link |
---|---|
US (1) | US6211244B1 (de) |
EP (4) | EP0787122B9 (de) |
JP (3) | JP2882882B2 (de) |
KR (2) | KR100403094B1 (de) |
CN (2) | CN1147459C (de) |
AT (2) | ATE359259T1 (de) |
AU (1) | AU709303B2 (de) |
BR (1) | BRPI9509411B8 (de) |
CA (1) | CA2202879C (de) |
CZ (2) | CZ290670B6 (de) |
DE (4) | DE122005000033I2 (de) |
DK (1) | DK1203761T3 (de) |
ES (2) | ES2234768T3 (de) |
FR (1) | FR05C0029I2 (de) |
HK (4) | HK1002454A1 (de) |
HU (2) | HU229474B1 (de) |
LU (1) | LU91182I2 (de) |
NL (1) | NL300199I2 (de) |
NZ (1) | NZ297157A (de) |
PL (1) | PL183499B1 (de) |
PT (1) | PT1203761E (de) |
RU (1) | RU2195446C2 (de) |
TW (2) | TW200402407A (de) |
UA (1) | UA55374C2 (de) |
WO (1) | WO1996012697A2 (de) |
Families Citing this family (142)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
PT1203761E (pt) * | 1994-10-21 | 2005-04-29 | Nps Pharma Inc | Compostos activos do receptor de calcio |
WO1997005252A2 (en) * | 1995-07-26 | 1997-02-13 | Nps Pharmaceuticals, Inc. | Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases |
EP1258471B1 (de) * | 1996-05-01 | 2007-01-24 | Nps Pharmaceuticals, Inc. | Verbindungen, die auf anorganische Ionen-Rezeptoren wirken |
EP1770083B1 (de) * | 1996-05-01 | 2009-04-29 | Nps Pharmaceuticals, Inc. | Inorganische am Ionen-Rezeptor aktive Verbindungen |
AU731146C (en) * | 1996-05-01 | 2005-02-03 | Nps Pharmaceuticals, Inc. | Inorganic ion receptor-active compounds |
US6362231B1 (en) * | 1996-07-08 | 2002-03-26 | Nps Pharmaceuticals, Inc. | Calcium receptor active compounds |
US6210964B1 (en) * | 1997-08-18 | 2001-04-03 | The Brigham And Women's Hospital, Inc. | Avian extracellular calcium-sensing receptor |
US6172091B1 (en) | 1998-10-14 | 2001-01-09 | Ortho-Mcneil Pharmaceutical, Inc. | 1,2-Disubstituted cyclopropanes |
US20040214889A1 (en) * | 1999-07-31 | 2004-10-28 | Smithkline Beecham Corporation | Calcilytic compounds |
DE60036758T2 (de) * | 1999-08-04 | 2008-07-24 | Sumitomo Chemical Co., Ltd. | Verfahren zur Herstellung von optisch aktiver 3,3,3-Trifluor-2-hydroxy-2-methylpropionsäure und deren Salze |
JP4595178B2 (ja) * | 1999-08-04 | 2010-12-08 | 住友化学株式会社 | アミン化合物、中間体、製造法および光学分割剤 |
US6797842B2 (en) * | 2000-05-11 | 2004-09-28 | Central Glass Company, Limited | Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same |
FR2809396B1 (fr) * | 2000-05-24 | 2005-10-14 | Centre Nat Rech Scient | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation |
AR038658A1 (es) * | 2001-06-15 | 2005-01-26 | Novartis Ag | Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento |
US6908935B2 (en) | 2002-05-23 | 2005-06-21 | Amgen Inc. | Calcium receptor modulating agents |
US7176322B2 (en) * | 2002-05-23 | 2007-02-13 | Amgen Inc. | Calcium receptor modulating agents |
US6849761B2 (en) | 2002-09-05 | 2005-02-01 | Wyeth | Substituted naphthoic acid derivatives useful in the treatment of insulin resistance and hyperglycemia |
GB0230015D0 (en) * | 2002-12-23 | 2003-01-29 | Novartis Ag | Organic compounds |
US7105537B2 (en) * | 2003-01-28 | 2006-09-12 | Bristol-Myers Squibb Company | 2-substituted cyclic amines as calcium sensing receptor modulators |
US7205322B2 (en) * | 2003-02-12 | 2007-04-17 | Bristol-Myers Squibb Company | Thiazolidine compounds as calcium sensing receptor modulators |
US7265145B2 (en) * | 2003-05-28 | 2007-09-04 | Bristol-Myers Squibb Company | Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method |
FR2855754B1 (fr) * | 2003-06-05 | 2005-07-08 | Oreal | Compsition, notamment cosmetique, comprenant une amine carbonylee |
PT1663182E (pt) * | 2003-09-12 | 2013-03-14 | Amgen Inc | Formulação de dissolução rápida de cinacalcet hcl |
US20050186658A1 (en) * | 2003-10-17 | 2005-08-25 | Nps Pharmaceuticals, Inc. | Chimeric metabotropic glutamate receptors and uses thereof |
EP1757582B1 (de) | 2004-05-28 | 2015-12-30 | Mitsubishi Tanabe Pharma Corporation | Arylalkylamine und verfahren zu deren herstellung |
US20050288377A1 (en) * | 2004-06-14 | 2005-12-29 | Cantor Thomas L | Use of calcimimetic as an adynamic bone disease related treatment |
CN1989097A (zh) * | 2004-07-22 | 2007-06-27 | 帝斯曼知识产权资产管理有限公司 | 用于制备非对映异构体富集的化合物的方法 |
US7361789B1 (en) | 2004-07-28 | 2008-04-22 | Amgen Inc. | Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis |
AU2006227429A1 (en) * | 2005-03-17 | 2006-09-28 | Amgen Inc. | Methods of decreasing calcification |
FR2885129B1 (fr) | 2005-04-29 | 2007-06-15 | Proskelia Sas | Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation. |
WO2006125026A2 (en) * | 2005-05-16 | 2006-11-23 | Teva Pharmaceutical Industries, Ltd. | Process for preparing cinacalcet hydrochloride |
CA2605736A1 (en) * | 2005-05-23 | 2006-11-30 | Teva Pharmaceutical Industries Ltd. | Purification of cinacalcet |
CA2605764A1 (en) * | 2005-05-23 | 2006-11-30 | Teva Pharmaceutical Industries Ltd. | Amorphous cinacalcet hydrochloride and preparation thereof |
AU2006285080B2 (en) * | 2005-09-02 | 2012-05-03 | Amgen Inc. | Methods of modulating intestinal fluid balance |
US7595161B2 (en) | 2005-11-10 | 2009-09-29 | Hansjoerg Martin Rothe | Efficacy of calcimimetic agents |
JP2009516655A (ja) * | 2005-11-22 | 2009-04-23 | テバ ファーマシューティカル インダストリーズ リミティド | シナカルセット塩酸塩の結晶形フォーム(Form)、およびそれらの調製方法 |
US7875609B2 (en) * | 2005-11-25 | 2011-01-25 | Galapagos Sasu | Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them |
US20070129444A1 (en) * | 2005-12-06 | 2007-06-07 | Mallinckrodt Inc. | Novel weight reduction composition and uses thereof |
ES2593047T3 (es) | 2006-02-03 | 2016-12-05 | Opko Renal, Llc | Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3 |
CA2645494C (en) * | 2006-03-23 | 2016-01-12 | Amgen Inc. | Methods and compositions for making and using polymorphs of cinacalcet |
CA2648939C (en) | 2006-04-20 | 2014-07-08 | Amgen Inc. | Stable emulsion formulations |
DE602007003067D1 (de) * | 2006-04-27 | 2009-12-17 | Teva Pharma | Verfahren zur herstellung einer cinacalcetbase |
EP1928817A1 (de) * | 2006-04-27 | 2008-06-11 | Teva Pharmaceutical Industries Ltd | Verfahren zur herstellung von cinacalcetbase |
ES2670029T3 (es) | 2006-06-21 | 2018-05-29 | Opko Ireland Global Holdings, Ltd. | Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D |
WO2008000423A1 (en) * | 2006-06-27 | 2008-01-03 | Sandoz Ag | Crystalline form of cinacalcet |
EP2069285A1 (de) * | 2006-06-27 | 2009-06-17 | Sandoz AG | Amorphe form von cinacalcet |
EP1914224A1 (de) * | 2006-10-19 | 2008-04-23 | Sandoz AG | Amorphes Cinacalcethydrochlorid |
GB0613674D0 (en) * | 2006-07-10 | 2006-08-16 | Proskelia Sas | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
US20080181959A1 (en) * | 2006-09-01 | 2008-07-31 | Ilan Zalit | Solid composites of a calcium receptor-active compound |
KR101129868B1 (ko) * | 2006-10-04 | 2012-04-12 | 화이자 프로덕츠 인코포레이티드 | 칼슘 수용체 길항제로서의 피리도[4,3-d]피리미딘-4(3H)-온 유도체 |
CA2672956C (en) * | 2006-10-26 | 2015-02-10 | Amgen Inc. | Calcium receptor modulating agents |
WO2008058236A2 (en) * | 2006-11-08 | 2008-05-15 | Dr. Reddy's Labortories, Ltd. | Methods for preparing cinacalcet hydrochloride |
WO2008063645A1 (en) * | 2006-11-20 | 2008-05-29 | Teva Pharmaceutical Industries Ltd. | Process for preparing cinacalcet |
EP2114390A2 (de) * | 2006-12-15 | 2009-11-11 | Ruprecht-Karls-Universität Heidelberg | Verfahren zur behandlung von erkrankungen im zusammenhang mit podozyten |
AU2008233088B2 (en) | 2007-03-30 | 2013-09-26 | Amgen Inc. | Calcimimetic compounds for use in the treatment of bowel disorders |
WO2008122010A1 (en) * | 2007-04-02 | 2008-10-09 | Concert Pharmaceuticals, Inc. | Pharmaceutical calcimimetics |
DK2148684T3 (da) | 2007-04-25 | 2013-04-22 | Cytochroma Inc | Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens |
EP2762132A1 (de) | 2007-04-25 | 2014-08-06 | Cytochroma Inc. | Orale Zusammensetzungen mit kontrollierter Freisetzung mit einer Vitamin-D-Verbindung und einem wachsartigen Träger |
JP5321452B2 (ja) * | 2007-05-08 | 2013-10-23 | 味の素株式会社 | 下痢の予防又は治療剤 |
WO2009002427A2 (en) | 2007-06-21 | 2008-12-31 | Amgen Inc. | Methods of synthesizing cinacalcet and salts thereof |
ITMI20071261A1 (it) | 2007-06-22 | 2008-12-23 | Dipharma Francis Srl | Procedimento per la preparazione di cinacalcet |
AU2008275595B2 (en) | 2007-07-10 | 2013-11-14 | Amgen Inc. | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
WO2009025792A2 (en) * | 2007-08-16 | 2009-02-26 | Teva Pharmaceutical Industries Ltd. | Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof |
WO2009065406A2 (en) * | 2007-11-23 | 2009-05-28 | Leo Pharma A/S | Novel cyclic hydrocarbon compounds for the treatment of diseases |
CA2716780A1 (en) | 2008-02-25 | 2009-09-03 | National University Corporation Hokkaido University | Prophylactic or therapeutic agent for diabetes or obesity |
JPWO2009107579A1 (ja) * | 2008-02-25 | 2011-06-30 | 味の素株式会社 | コク味付与剤 |
WO2009119554A1 (ja) | 2008-03-24 | 2009-10-01 | 味の素株式会社 | 消化管の重炭酸分泌促進剤 |
AU2009228069B9 (en) * | 2008-03-28 | 2014-07-10 | Amgen Inc. | Calcimimetic compound for use in the treatment of epithelial injury |
EP2286836A4 (de) | 2008-04-17 | 2011-10-12 | Ajinomoto Kk | Immunstimulierendes mittel |
EP2321256B1 (de) * | 2008-06-18 | 2014-11-12 | ERREGIERRE S.p.A. | Verfahren zur synthese von cinacalcet hydrochlorid |
WO2010015935A2 (en) * | 2008-08-06 | 2010-02-11 | Actavis Group Ptc Ehf | Unsaturated cinacalcet salts and processes for preparing cinacalcet hydrochloride |
US9133140B2 (en) | 2008-08-22 | 2015-09-15 | Daiichi Sankyo Company, Limited | Cycloalkylamne derivatives |
WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
EP2376424A1 (de) | 2008-12-08 | 2011-10-19 | Actavis Group PTC EHF | Hochreines cinacalcet oder pharmazeutisch unbedenkliches salz davon |
EP2389362B1 (de) | 2009-01-21 | 2019-12-11 | Oryzon Genomics, S.A. | Phenylcyclopropylaminderivate und deren medizinische verwendung |
WO2010086129A1 (en) | 2009-01-27 | 2010-08-05 | Rathiopharm Gmbh | Inclusion complex comprising cinacalcet and cyclodextrin |
CA2748595C (en) | 2009-02-19 | 2017-03-14 | Zach System S.P.A. | Process for preparing cinacalcet hydrochloride |
JP2012519677A (ja) | 2009-03-05 | 2012-08-30 | シプラ・リミテッド | シナカルセト及びその塩の製造方法、並びに該方法に使用する中間体 |
WO2010103531A2 (en) | 2009-03-09 | 2010-09-16 | Megafine Pharma (P) Ltd. | A new method for the preparation of cinacalcet and new intermediates thereof |
WO2010103429A1 (en) | 2009-03-10 | 2010-09-16 | Pfizer Inc. | 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists |
WO2010104882A1 (en) | 2009-03-10 | 2010-09-16 | Amgen Inc. | Methods of modulating sperm motility |
AU2010234518A1 (en) * | 2009-04-09 | 2012-02-02 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
WO2010128388A2 (en) | 2009-05-08 | 2010-11-11 | Aurobindo Pharma Limited | An improved process for the preparation of intermediate compounds useful for the preparation of cinacalcet |
US8765676B2 (en) | 2009-05-27 | 2014-07-01 | Leo Pharma A/S | Calcium sensing receptor modulating compounds and pharmaceutical use thereof |
EP2435400A2 (de) | 2009-05-27 | 2012-04-04 | Leo Pharma A/S | Neue, den calcium sensing receptor modulierende verbindungen und deren pharmazeutische verwendung |
WO2010150837A1 (ja) * | 2009-06-25 | 2010-12-29 | 第一三共株式会社 | インドリン誘導体 |
ES2547730T3 (es) | 2009-07-31 | 2015-10-08 | Cognition Therapeutics, Inc. | Inhibidores del deterioro cognitivo |
CA2769659C (en) | 2009-09-10 | 2017-10-24 | Zach System S.P.A. | Process for preparing cinacalcet |
US8759586B2 (en) | 2009-09-16 | 2014-06-24 | Ranbaxy Laboratories Limited | Processes for the preparation of cinacalcet |
CN102639496B (zh) | 2009-09-25 | 2014-10-29 | 奥瑞泽恩基因组学股份有限公司 | 赖氨酸特异性脱甲基酶-1抑制剂及其应用 |
US8722732B2 (en) | 2009-09-29 | 2014-05-13 | Nektar Therapeutics | Oligomer-calcimimetic conjugates and related compounds |
AU2010315805B2 (en) | 2009-09-29 | 2015-09-17 | Nektar Therapeutics | Oligomer-calcimimetic conjugates and related compounds |
EP2486002B1 (de) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituierte heteroaryl- und arylcyclopropylaminacetamide und ihre verwendung |
EP2314286A1 (de) | 2009-10-21 | 2011-04-27 | Ratiopharm GmbH | Schmelzgranuliertes Cinacalcet |
WO2011050499A1 (zh) * | 2009-11-02 | 2011-05-05 | 上海威智医药科技有限公司 | 盐酸西那卡塞的合成方法 |
IT1396623B1 (it) * | 2009-11-26 | 2012-12-14 | Dipharma Francis Srl | Procedimento per la preparazione di cinacalcet e suoi intermedi |
WO2011106573A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
US9616058B2 (en) | 2010-02-24 | 2017-04-11 | Oryzon Genomics, S.A. | Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use |
PT2552484T (pt) | 2010-03-29 | 2020-04-03 | Opko Ireland Global Holdings Ltd | Métodos e composições para redução dos níveis de parafróides |
BR112012026694A2 (pt) | 2010-04-19 | 2016-07-12 | Oryzon Genomics Sa | inibidores da desmetilase específica para lisina 1 e seu uso |
WO2011146583A2 (en) | 2010-05-19 | 2011-11-24 | Elan Pharma International Limited | Nanoparticulate cinacalcet formulations |
JP5968881B2 (ja) | 2010-06-30 | 2016-08-10 | レオ ファーマ アクティーゼルスカブ | カルシウム模倣化合物の新規多形 |
CN102958907A (zh) | 2010-06-30 | 2013-03-06 | 利奥制药有限公司 | 钙敏感受体激动化合物的新多晶型 |
US8921606B2 (en) * | 2010-07-16 | 2014-12-30 | Hetero Research Foundation | Process for cinacalcet hydrochloride |
WO2012013728A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use |
WO2012013727A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
US9061966B2 (en) | 2010-10-08 | 2015-06-23 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
CN101993379B (zh) * | 2010-10-22 | 2013-06-19 | 能特科技股份有限公司 | 一种盐酸西那卡塞的制备方法 |
JP2014500882A (ja) | 2010-11-26 | 2014-01-16 | レオ ファーマ アクティーゼルスカブ | カルシウム感知受容体活性化合物 |
RU2013128981A (ru) | 2010-11-26 | 2015-01-10 | Лео Фарма А/С | Соединения, активные в отношении чувствительных к кальцию рецепторов |
WO2012069421A1 (en) | 2010-11-26 | 2012-05-31 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
WO2012069419A1 (en) | 2010-11-26 | 2012-05-31 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
US8846941B2 (en) | 2010-12-13 | 2014-09-30 | Quiapeg Ab | Functionalized polymers |
WO2012107498A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
RU2681211C2 (ru) | 2011-10-20 | 2019-03-05 | Оризон Дженомикс С.А. | (гетеро)арилциклопропиламины в качестве ингибиторов lsd1 |
SG11201401066PA (en) | 2011-10-20 | 2014-10-30 | Oryzon Genomics Sa | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
CZ2011770A3 (cs) | 2011-11-25 | 2013-01-16 | Zentiva, K.S. | Zpusob výroby Cinacalcetu |
CN103450027B (zh) | 2012-05-29 | 2015-07-29 | 上海京新生物医药有限公司 | 盐酸西那卡塞的制备方法 |
US10010621B2 (en) | 2012-06-12 | 2018-07-03 | Quiapeg Pharmaceuticals Ab | Conjugates of biologically active molecules to functionalized polymers |
US20150344407A1 (en) * | 2012-08-21 | 2015-12-03 | The Board Of Regents Of The University Of Texas System | Fendiline derivatives and methods of use thereof |
IN2015MN00421A (de) * | 2012-08-27 | 2015-09-04 | Lupin Ltd | |
FR2995307A1 (fr) | 2012-09-07 | 2014-03-14 | Prod Chim Auxiliaires Et De Synthese | Procede de preparation du cinacalcet et de ses sels pharmaceutiquement acceptables |
DK2730279T3 (en) | 2012-11-09 | 2015-10-26 | K H S Pharma Holding Gmbh | CINACALCETFORMULERINGER immediate release |
US9895325B2 (en) | 2012-12-21 | 2018-02-20 | Synthon B.V. | Tablet composition comprising cinacalcet hydrochloride |
KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 d 방출 제형 |
EP3013324A1 (de) | 2013-06-26 | 2016-05-04 | Jubilant Generics Limited | Sprengmittelfreie zusammensetzung von cinacalcet |
DK3498692T3 (da) | 2014-01-31 | 2022-05-16 | Cognition Therapeutics Inc | Isoindolin-sammensætninger og fremgangsmåder til behandling af neurodegenerativ sygdom og makulær degeneration |
WO2015183839A1 (en) | 2014-05-27 | 2015-12-03 | Cardioxyl Pharmaceuticals, Inc. | Pyrazolone derivatives as nitroxyl donors |
CN104045568A (zh) * | 2014-06-18 | 2014-09-17 | 中山奕安泰医药科技有限公司 | 一种合成(r)-1–(萘-1-基)乙胺的新工艺 |
SG10201911274TA (en) | 2014-08-07 | 2020-02-27 | Opko Ireland Global Holdings Ltd | Adjunctive therapy with 25-hydroxyvitamin d |
CN104478736B (zh) * | 2014-12-16 | 2016-07-13 | 成都启泰医药技术有限公司 | 一种盐酸西那卡塞的制备方法 |
US20180155270A1 (en) | 2015-05-29 | 2018-06-07 | Lupin Limited | Process for preparation of cinacalcet intermediate and cinacalcet hydrochloride |
TWI747893B (zh) | 2016-03-28 | 2021-12-01 | 愛爾蘭商歐科愛爾蘭全球控股股份有限公司 | 維生素d治療之方法 |
WO2018163131A1 (en) | 2017-03-10 | 2018-09-13 | Quiapeg Pharmaceuticals Ab | Releasable conjugates |
BR112019023851A2 (pt) | 2017-05-15 | 2020-08-18 | Cognition Therapeutics, Inc. | compostos, suas composições farmacêuticas e métodos para tratamento de doenças neurodegenerativas |
EP3849660A1 (de) | 2018-09-12 | 2021-07-21 | QuiaPEG Pharmaceuticals AB | Lösbare glp-1-konjugate |
CN111196759B (zh) * | 2018-11-16 | 2023-03-24 | 上海博志研新药物技术有限公司 | 盐酸西那卡塞及其中间体的制备方法 |
US20220313581A1 (en) * | 2019-08-28 | 2022-10-06 | Conopco, Inc. , d/b/a UNILEVER | Novel compounds for skin lightening |
EP4125840A1 (de) | 2020-03-27 | 2023-02-08 | Som Innovation Biotech, S.A. | Verbindungen zur verwendung bei der behandlung von synukleinopathien |
RU2739376C1 (ru) * | 2020-07-24 | 2020-12-23 | Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) | Способ получения фендилина |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2276618A (en) | 1942-03-17 | N-phenylaliphatic bihxdroxithenyl- | ||
US2930731A (en) | 1952-04-08 | 1960-03-29 | Upjohn Co | Bis[beta-(ortho-hydrocarbonoxyphenyl)iso-propyl]amines |
BE570596A (de) | 1957-08-26 | |||
BE621300A (de) | 1961-08-14 | |||
US3262977A (en) | 1962-03-10 | 1966-07-26 | Chinoin Gyogyszer Es Vegyeszet | N-aralkyl-1, 1-diphenyl-propylamine derivatives |
NL293886A (de) | 1962-06-19 | 1965-04-12 | Merck Ag E | |
US3318952A (en) * | 1964-01-22 | 1967-05-09 | Sandoz Ag | Dibenzylsulfamides |
US3459767A (en) | 1965-08-10 | 1969-08-05 | Pfizer & Co C | Aminomethylindoles |
GB1109924A (en) | 1965-11-29 | 1968-04-18 | Roche Products Ltd | Novel substituted diphenylalkyl amines and a process for the manufacture thereof |
DE1618005A1 (de) | 1966-09-22 | 1971-09-09 | Thomae Gmbh Dr K | Verfahren zur Herstellung von neuen Amino-dihalogen-phenyl-aethylaminen |
CH480791A (de) | 1967-01-17 | 1969-11-15 | Ciba Geigy | Schädlingsbekämpfungsmittel |
GB1263987A (en) | 1969-05-30 | 1972-02-16 | Allen & Hanburys Ltd | Phenethylamine derivatives |
US4129598A (en) * | 1972-05-31 | 1978-12-12 | Synthelabo | Phenylethylamine derivatives |
GB1448437A (en) | 1973-02-24 | 1976-09-08 | Beecham Group Ltd | Diphenylpropylamines |
US3862925A (en) | 1973-07-05 | 1975-01-28 | American Home Prod | Preparation of somatotropin release inhibiting factor and intermediates therefor |
US4000197A (en) * | 1973-07-23 | 1976-12-28 | The University Of Iowa Research Foundation | Asymmetric synthesis of phenylisopropylamines |
US3842067A (en) | 1973-07-27 | 1974-10-15 | American Home Prod | Synthesis of(des-asn5)-srif and intermediates |
JPS5726506B2 (de) | 1974-03-08 | 1982-06-04 | ||
US4014937A (en) | 1974-08-26 | 1977-03-29 | Pfizer Inc. | 3,4-And 3,5-dialkoxyphenethylamines |
HU169507B (de) * | 1974-09-25 | 1976-12-28 | ||
US3987201A (en) | 1974-12-24 | 1976-10-19 | Eli Lilly And Company | Method for treating arrhythmia |
US4105602A (en) | 1975-02-10 | 1978-08-08 | Armour Pharmaceutical Company | Synthesis of peptides with parathyroid hormone activity |
JPS5390272A (en) | 1977-01-13 | 1978-08-08 | Sendai Fukusokan Kagaku Kenkiy | Method of producing optically active salsolizine |
US4608391A (en) | 1977-07-05 | 1986-08-26 | Cornell Research Foundation Inc. | Catecholamine derivatives, a process for their preparation and pharmaceutical compositions thereof |
US4289787A (en) | 1977-12-19 | 1981-09-15 | Eli Lilly And Company | Quaternary ammonium antiarrhythmic drugs |
DD144050A5 (de) | 1978-06-05 | 1980-09-24 | Ciba Geigy Ag | Verfahren zur herstellung von n-alkylierten aminoalkoholen |
DE2825961A1 (de) | 1978-06-14 | 1980-01-03 | Basf Ag | Fungizide amine |
US4391826A (en) | 1978-07-03 | 1983-07-05 | Eli Lilly And Company | Phenethanolamines, compositions containing the same, and method for effecting weight control |
IL57672A (en) | 1978-07-03 | 1983-03-31 | Lilly Co Eli | Phenethanolamines,their preparation and pharmaceutical compositions containing the same |
ZA794872B (en) | 1978-09-20 | 1980-11-26 | Schering Corp | A phenylalkylaminoethylsalicylamide,its preparation and pharmaceutical compositions containing it |
DE2841184C2 (de) * | 1978-09-22 | 1986-09-25 | Hochtemperatur-Reaktorbau GmbH, 4600 Dortmund | Vorrichtung zur Durchmischung der Heißgassträhnen bei einem gasgekühlten Hochtemperaturreaktor |
FR2436773A1 (fr) | 1978-09-22 | 1980-04-18 | Roussel Uclaf | Nouveaux derives du 3-(aminoethyl) phenol et leurs sels, procede de preparation et application a titre de medicaments |
US4360511A (en) | 1978-11-29 | 1982-11-23 | Medi-Physics, Inc. | Amines useful as brain imaging agents |
DD150456A5 (de) | 1979-03-01 | 1981-09-02 | Ciba Geigy Ag | Verfahren zur herstellung von derivaten des 3-amino-1,2-propandiols |
EP0023385B1 (de) | 1979-06-16 | 1982-12-15 | Beecham Group Plc | Äthanamin-Derivate, ihre Herstellung und Verwendung in pharmazeutischen Zusammensetzungen |
JPS603387B2 (ja) | 1980-07-10 | 1985-01-28 | 住友化学工業株式会社 | 新規光学活性イミダゾリジン−2−オン誘導体およびその製法 |
HU183430B (en) | 1981-05-12 | 1984-05-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing cyclodextrine inclusion complexes of n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine or n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine-hydrochloride |
US4591605A (en) | 1981-11-10 | 1986-05-27 | Research Foundation Of State University Of New York | Method and ingestible formulation for inhibiting the secretion of stomach acid |
US4658060A (en) | 1982-04-26 | 1987-04-14 | Schering Corporation | Preparation of (-)-5-(beta)-1-hydroxy-2-((beta)-1-methyl-3-phenylpropyl)aminoethyl) salicylamide |
DE3225879A1 (de) | 1982-07-10 | 1984-01-12 | Basf Ag, 6700 Ludwigshafen | Trans-3-(4'-tert.-butylcyclohexyl-1')-2-methyl-1-dialkyl-aminopropane, ihre herstellung und verwendung als arzneimittel |
CA1258454A (en) | 1982-08-10 | 1989-08-15 | Leo Alig | Phenethanolamines |
US4647446A (en) | 1982-08-18 | 1987-03-03 | The Regents Of The University Of California | Rapid brain scanning radiopharmaceutical |
JPS5950358A (ja) | 1982-09-14 | 1984-03-23 | Sumitomo Chem Co Ltd | 光学活性なカルボン酸をグラフトしたクロマトグラフ充填剤およびそれを用いる鏡像体混合物の分離法 |
US4677101A (en) | 1983-09-26 | 1987-06-30 | Merck & Co., Inc. | Substituted dihydroazepines useful as calcium channel blockers |
US4661635A (en) | 1983-11-21 | 1987-04-28 | Mcneilab, Inc. | Aralykyl (arylethynyl)aralkyl amines and their use as vasodilators and antihypertensives |
DE3405333A1 (de) * | 1984-02-15 | 1985-08-22 | Sandoz-Patent-GmbH, 7850 Lörrach | Neue allylamine, verfahren zu ihrer herstellung und ihre verwendung |
US5334628A (en) | 1984-06-09 | 1994-08-02 | Kaken Pharmaceutical Co., Ltd. | Amine derivatives, processes for preparing the same and fungicides containing the same |
US4587253A (en) | 1984-07-30 | 1986-05-06 | Merck & Co., Inc. | Bridged pyridine compounds useful as calcium channel blockers and analgesics |
US4609494A (en) | 1985-02-21 | 1986-09-02 | Merck & Co., Inc. | 5-acetyl-3,4,5,6-tetrahydro-4-oxo-2,6-methano-2H-1,3,5-benzothiazocine(benzodiazocine)-11-carboxylates useful as calcium channel blockers |
US4839369A (en) | 1985-04-16 | 1989-06-13 | Rorer Pharmaceutical Corporation | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments |
GB8522186D0 (en) | 1985-09-06 | 1985-10-09 | Erba Farmitalia | Cycloalkyl-substituted 4-aminophenyl derivatives |
DE3541181A1 (de) | 1985-11-21 | 1987-05-27 | Basf Ag | Propylamine, verfahren zu ihrer herstellung und ihre verwendung als fungizide |
US4675321A (en) | 1986-02-07 | 1987-06-23 | Merck & Co., Inc. | Substituted pyrimidines useful as calcium channel blockers |
US5034514A (en) | 1986-03-17 | 1991-07-23 | Cetus Corporation | Novel cross-linking agents |
US5030576A (en) | 1986-04-30 | 1991-07-09 | Genentech, Inc. | Receptors for efficient determination of ligands and their antagonists or agonists |
US4808718A (en) | 1986-05-06 | 1989-02-28 | Merck & Co., Inc. | Fused polycyclic and bridged compounds useful as calcium channel blockers |
HU200591B (en) | 1986-07-11 | 1990-07-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing new diphenyl propylamine derivatives and pharmaceutical compositions comprising such compounds |
IL83163A (en) | 1986-07-18 | 1991-06-10 | Erba Carlo Spa | Cycloalkyl-substituted 4-pyridyl derivatives,their preparation and pharmaceutical compositions containing them |
HU207280B (en) | 1986-09-25 | 1993-03-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing new phenyl-alkyl-amines and pharmaceutical compositions containing them |
US4925664A (en) | 1986-10-20 | 1990-05-15 | University Of Utah | Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function |
US5064657A (en) | 1986-10-20 | 1991-11-12 | University Of Utah | Spider toxins and methods for their use as blockers of amino acid receptor function |
EP0270376B1 (de) | 1986-12-04 | 1992-09-30 | Asahi Kasei Kogyo Kabushiki Kaisha | Vom Calcitonin-Gen abgeleitete Peptidderivate |
GB8720115D0 (en) | 1987-08-26 | 1987-09-30 | Cooper G J S | Treatment of diabetes mellitus |
GB8709871D0 (en) | 1987-04-27 | 1987-06-03 | Turner R C | Peptides |
US4916145A (en) | 1987-07-10 | 1990-04-10 | Hoffmann-La Roche Inc. | Substituted n-[(pyridyl)alkyl]aryl-carboxamide |
DE68924372T2 (de) | 1988-01-11 | 1996-05-09 | Amylin Pharmaceuticals Inc | Behandlung von diabetes mellitus typ 2. |
US5001251A (en) | 1988-01-15 | 1991-03-19 | E. R. Squibb & Sons, Inc. | Optical resolution of DL-3-acylthio-2-methylpropanoic acid |
EP0424397B1 (de) | 1988-04-04 | 1996-06-19 | The Salk Institute Biotechnology Industrial Associates, Inc. | Calciumkanal-zusammensetzungen und verfahren |
US5082837A (en) | 1988-06-28 | 1992-01-21 | Merrell Dow Pharmaceuticals | Lactamimides as calcium antagonists |
US4925873A (en) | 1988-09-01 | 1990-05-15 | E. R. Squibb & Sons, Inc. | Method of treating skin injuries using thromboxane A2 receptor antagonists |
JPH02200658A (ja) | 1989-01-28 | 1990-08-08 | Kumiai Chem Ind Co Ltd | N―(置換)ベンジルカルボン酸アミド誘導体及び除草剤 |
RU2005717C1 (ru) * | 1989-02-17 | 1994-01-15 | Такеда кемикал-индастриз Лтд | Способ получения производных аралкиламинов или их кислотно-аддитивных солей |
US5011834A (en) | 1989-04-14 | 1991-04-30 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | PCP receptor ligands and the use thereof |
DD298412A5 (de) | 1989-04-28 | 1992-02-20 | ������@���Kk�� | Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele |
EP0597830A1 (de) | 1989-07-03 | 1994-05-25 | New York University Nyu Medical Center | Verwendung von Polyaminen als die Ionenkanäle regulierenden Wirkstoffe |
GB8915712D0 (en) | 1989-07-08 | 1989-08-31 | Macintyre Iain | Medical treatment |
US5021599A (en) | 1989-08-31 | 1991-06-04 | Serpentix Conveyor Corporation | Redox-responsive anion receptors |
US5053337A (en) | 1989-10-30 | 1991-10-01 | Neurogenetic Corporation | DNA encoding an α2B -adrenergic receptor |
EP0507863A4 (en) | 1989-12-28 | 1993-07-07 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
JP2818958B2 (ja) | 1990-02-23 | 1998-10-30 | 塩野義製薬株式会社 | 4―(4―アルコキシフェニル)―2―ブチルアミン誘導体およびその製造法 |
US5096908A (en) | 1990-05-04 | 1992-03-17 | Eli Lilly And Company | Method of inhibiting gastric acid secretion |
WO1992007829A1 (en) | 1990-11-02 | 1992-05-14 | The Upjohn Company | Indole-3-methanamines useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents |
EP0940139B1 (de) | 1991-02-08 | 2005-02-02 | Scion Pharmaceuticals, Inc. | Substituierte Guanidine und Derivate hiervon als Modulatoren der Freisetzung von Neurotransmittern und neue Methode zur Identifizierung von Inhibitoren der Neurotransmitter-Freisetzung |
US5312928A (en) | 1991-02-11 | 1994-05-17 | Cambridge Neuroscience | Calcium channel antagonists and methodology for their identification |
DE69206306T2 (de) * | 1991-04-08 | 1996-06-13 | Sumitomo Chemical Co | Optisch aktive Sekundär-Aminverbindung, Verfahren zur Herstellung einer optisch aktiven Sekundär-Aminverbindung und Verfahren zur Herstellung optisch aktiver Carbonsäure durch die Verwendung dieser Verbindung. |
US5688938A (en) | 1991-08-23 | 1997-11-18 | The Brigham & Women's Hospital, Inc. | Calcium receptor-active molecules |
ES2218531T3 (es) * | 1991-08-23 | 2004-11-16 | Nps Pharmaceuticals, Inc. | Arilalquilaminas activas sobre los receptores del calcio. |
MX9204881A (es) * | 1991-08-23 | 1993-04-01 | Nps Pharma Inc | Composicion farmaceutica que comprende moleculas activas, receptoras de calcio. |
US5763569A (en) | 1991-08-23 | 1998-06-09 | The Brigham And Women's Hospital, Inc | Calcium receptor-active molecules |
EP0613458B1 (de) | 1991-11-12 | 1998-01-07 | Pfizer Inc. | Azyklische ethylendiaminderivate als 'substance p rezeptor' antagonisten |
EP0620809B1 (de) | 1991-12-30 | 1997-03-05 | Janssen Pharmaceutica N.V. | Alpha-substituierte benzenmethanamin-derivate |
WO1993015044A1 (en) | 1992-01-29 | 1993-08-05 | Smithkline Beecham Corporation | N-benzyloxamic acid, oxamate, and oxamide derivatives and their use as tnf and pde iv inhibitors |
JP3175339B2 (ja) * | 1992-10-07 | 2001-06-11 | 住友化学工業株式会社 | 光学活性アミン化合物、その製法、その中間体及びその用途 |
KR100296899B1 (ko) * | 1993-02-23 | 2001-10-24 | 쉘비 칼베르그 모르스 | 칼슘수용체활성분자 |
JP2964639B2 (ja) | 1993-05-19 | 1999-10-18 | 東レ株式会社 | 混繊複合仮撚糸およびその製造方法ならびにその糸を用いてなる編織物 |
US5631401A (en) * | 1994-02-09 | 1997-05-20 | Abbott Laboratories | Inhibitors of protein farnesyltransferase and squalene synthase |
PT1203761E (pt) * | 1994-10-21 | 2005-04-29 | Nps Pharma Inc | Compostos activos do receptor de calcio |
US7043457B1 (en) | 2000-06-28 | 2006-05-09 | Probuild, Inc. | System and method for managing and evaluating network commodities purchasing |
US20060283332A1 (en) | 2001-12-11 | 2006-12-21 | Garman Michael H | Hot beverage maker |
US8526300B2 (en) | 2008-03-31 | 2013-09-03 | Ericsson Ab | Method and apparatus for providing resiliency in multicast networks |
KR101411428B1 (ko) | 2012-07-12 | 2014-06-24 | 한국과학기술원 | 집광식 휴대용 형광 검출 시스템 |
-
1995
- 1995-10-23 PT PT01204920T patent/PT1203761E/pt unknown
- 1995-10-23 BR BRPI9509411 patent/BRPI9509411B8/pt active IP Right Grant
- 1995-10-23 AU AU41957/96A patent/AU709303B2/en not_active Expired
- 1995-10-23 PL PL95319812A patent/PL183499B1/pl unknown
- 1995-10-23 ES ES01204920T patent/ES2234768T3/es not_active Expired - Lifetime
- 1995-10-23 DE DE1995633948 patent/DE122005000033I2/de active Active
- 1995-10-23 DE DE200512000033 patent/DE122005000033I1/de active Pending
- 1995-10-23 DK DK01204920T patent/DK1203761T3/da active
- 1995-10-23 CA CA002202879A patent/CA2202879C/en not_active Expired - Lifetime
- 1995-10-23 CN CNB951970054A patent/CN1147459C/zh not_active Expired - Lifetime
- 1995-10-23 CN CNB021302251A patent/CN1312116C/zh not_active Expired - Fee Related
- 1995-10-23 ES ES95940547T patent/ES2285707T3/es not_active Expired - Lifetime
- 1995-10-23 DE DE69533948T patent/DE69533948T2/de not_active Expired - Lifetime
- 1995-10-23 HU HU0700718A patent/HU229474B1/hu unknown
- 1995-10-23 US US08/546,998 patent/US6211244B1/en not_active Expired - Lifetime
- 1995-10-23 JP JP8514118A patent/JP2882882B2/ja not_active Expired - Lifetime
- 1995-10-23 AT AT95940547T patent/ATE359259T1/de not_active IP Right Cessation
- 1995-10-23 EP EP95940547A patent/EP0787122B9/de not_active Expired - Lifetime
- 1995-10-23 EP EP04026530A patent/EP1553078A1/de not_active Withdrawn
- 1995-10-23 UA UA97052226A patent/UA55374C2/uk unknown
- 1995-10-23 HU HU9802491A patent/HU228150B1/hu active Protection Beyond IP Right Term
- 1995-10-23 KR KR10-2000-7003440A patent/KR100403094B1/ko not_active IP Right Cessation
- 1995-10-23 CZ CZ19971182A patent/CZ290670B6/cs not_active IP Right Cessation
- 1995-10-23 KR KR1019970702598A patent/KR100293621B1/ko not_active IP Right Cessation
- 1995-10-23 WO PCT/US1995/013704 patent/WO1996012697A2/en active IP Right Grant
- 1995-10-23 DE DE69535461T patent/DE69535461T2/de not_active Expired - Lifetime
- 1995-10-23 AT AT01204920T patent/ATE287390T1/de active
- 1995-10-23 NZ NZ297157A patent/NZ297157A/xx not_active IP Right Cessation
- 1995-10-23 EP EP02019566A patent/EP1275635A1/de not_active Withdrawn
- 1995-10-23 EP EP01204920A patent/EP1203761B1/de not_active Expired - Lifetime
- 1995-10-23 RU RU97108069/04A patent/RU2195446C2/ru not_active IP Right Cessation
- 1995-11-03 TW TW092127732A patent/TW200402407A/zh unknown
- 1995-11-03 TW TW084111615A patent/TW568896B/zh not_active IP Right Cessation
-
1998
- 1998-01-29 JP JP01656398A patent/JP4002338B2/ja not_active Expired - Fee Related
- 1998-02-03 HK HK98100781A patent/HK1002454A1/xx not_active IP Right Cessation
-
1999
- 1999-11-12 HK HK99105216A patent/HK1020041A1/xx not_active IP Right Cessation
-
2001
- 2001-10-21 CZ CZ20014662A patent/CZ292709B6/cs not_active IP Right Cessation
-
2002
- 2002-10-31 HK HK02107939.7A patent/HK1046900B/zh not_active IP Right Cessation
-
2003
- 2003-07-12 HK HK03105050.3A patent/HK1052685A1/zh unknown
-
2005
- 2005-06-10 NL NL300199C patent/NL300199I2/nl unknown
- 2005-06-30 FR FR05C0029C patent/FR05C0029I2/fr active Active
- 2005-07-18 LU LU91182C patent/LU91182I2/fr unknown
-
2007
- 2007-02-22 JP JP2007042364A patent/JP4353985B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69533948D1 (de) | Kalzium-Rezeptor aktive Verbindungen | |
ES2110421T3 (es) | O-bencil-oximeteres y los agentes protectores de las plantas que contienen estos compuestos. | |
DE3683175D1 (de) | Azolylmethyloxirane - ihre herstellung und verwendung als pflanzenschutzmittel. | |
SE8402188L (sv) | Fenetanolaminderivat | |
FI935091A0 (fi) | Foerfarande och anordning foer kanalbegaeran i ett kommunikationssystem | |
AR016978A1 (es) | Sulfonamidas naftil- y anilidido-substituidas, un proceso para su preparacion, uso de las mismas para la fabricacion de medicamentos y medicamentos que loscontienen | |
FI930852A (fi) | Foerledning foer bildande av ett roekgas ledande skorstensinnefoer av en husskorsten som behoever sanering, foerfarande foer framstaellning av en roerledning och anvaendning av densamma | |
NO306618B1 (no) | Farnesyloeproteintransferaseinhibitorer som anticancermidler | |
ES8602582A1 (es) | Un procedimiento para la preparacion de arilindan-1,3-dionas. | |
ES2097274T3 (es) | Composiciones polimericas autoextinguibles. | |
FI921408A (fi) | Foerfarande foer skjutning av en borrstaong in i ett utslagshaol av en schaktugn, borrmaskin och duppelriktad klaemma | |
FI915981A (fi) | Tejpupplindningspultrusionsprocess foer framstaellning profiler av foerstaerkningsplast och foerstaerkningsplastprofil som framstaellts med foerfarandet | |
FIU930448U0 (fi) | Maetapparat foer effekt och energi som oeverfoerts av ett elastiskt effekttransmissionsorgan saosom kedja, lina, vajer eller olika remmar | |
FI911240A (fi) | Faestningsyta foer ett gasmunsstycke i en svetsningsbraennare och foerfarande foer tillverkning daerav. | |
CS743087A2 (en) | Herbicide and method of its effective substances production | |
FI903322A0 (fi) | Foerfarande och anordning foer oeverfoering av energi. | |
FI905240A (fi) | Foerfarande och anordning foer ordnande av installation/loestagande av ett hjul i ett fordon. |